Salt Lake City, Utah, May 31, 2023/OrthoSpineNews/ – Kolosis BIO (Kolosis), a leading provider of biologics solutions, and MTF Biologics, a global tissue processor and nonprofit organization, are excited to announce their partnership in the surgical incision market. This strategic collaboration represents Kolosis BIO’s expansion into a new area of healthcare, while providing MTF with a focused partner to fully leverage the potential of their exceptional tissues in this market. Together, the two companies are dedicated to advancing surgical technologies and driving improvements in patient outcomes.
“We are thrilled to embark on this strategic partnership with MTF Biologics, a global leader in tissue processing,” said Collin Begley, CEO of Kolosis BIO. “Our longstanding relationship with MTF has been built on a foundation of trust, collaboration, and a shared commitment to innovation. Together, we are dedicated to bringing outstanding technologies to patients, and this expansion into surgical incision represents an exciting milestone for us. By leveraging our strong market channel and extending our reach beyond bone graft solutions, we are poised to deliver additional transformative product offerings to the operating room.”
Kim Rounds, Vice President & General Manager, Wound Care Franchise at MTF Biologics, expressed enthusiasm for the collaboration, stating, “This partnership with Kolosis allows MTF to add a strategic partner who can further leverage our best-in-class placental tissues to optimize surgical outcomes. The anti-microbial, anti-adhesive, and anti-inflammatory properties of human amniotic tissue can be beneficial in the presence of patient and /or incision healing risk factors. We are excited to work together to advance surgical incision care, specifically benefiting patients in the spine and orthopedic fields.”
This strategic partnership between Kolosis BIO and MTF Biologics marks a significant milestone in their shared mission to provide advanced solutions to healthcare providers and drive positive patient outcomes. The companies are excited about the opportunity to develop innovative technologies and establish new standards in surgical incision management, driving advancements in patient care.
About Kolosis BIO
Kolosis BIO is a leading provider of innovative biologic solutions, dedicated to commercializing cutting-edge technologies and delivering market-leading products to the orthopedic industry. As a pure-play biologics company, Kolosis BIO exclusively partners with MTF Biologics to offer superior quality bone graft technologies such as Kore Fiber, a 100% cortical fiber allograft and Prime HD, a pre-hydrated DBM. These allografts are backed by MTF’s proprietary aseptic processing methods that optimally preserve matrix structures and osteoinductive properties.
As the company looks to the future, Kolosis is dedicated to driving innovation in the biologics field, expanding its product offerings and pushing the boundaries of science to enhance patient outcomes. With a focus on relentless execution and bold technologies, Kolosis BIO endeavors to become a leading force in the biologics market. For more information, please visit www.kolosis.com.
About MTF Biologics
MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. They provide unmatched service, resources, and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists.
The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation), expands its reach to patients across the globe. For more information, visit www.mtfbiologics.org.